Articles From: BioShock® Infinite: Burial at Sea – Episode Two Available for Download Starting Today to Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year's USD$21.8 Million Loss from Operations


2014/3/25
2K and Irrational Games announced today that BioShock® Infinite: Burial at Sea – Episode Two is downloadable* in all available territories** on the PlayStation®3 computer entertainment system, Xbox 360 games and entertainment system from Microsoft and Windows PC starting today.
Sign-up for BioShock® Infinite: Burial at Sea – Episode Two Available for Download Starting Today investment picks
-- Proper naming of biosimilars key for patient access, safety --
Sign-up for Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting investment picks
2013/10/7
- Clinical Papers Presented on Four-Year Data from CORDLESS Recurrence Study and Three-Year Safety Data - - Positive Data Reported on Use of Local Anesthesia in Dupuytren's Contracture Procedures - LYNBROOK, N.Y. , Oct.
Sign-up for BioSpecifics Technologies Corp. Announces Data from Multiple Studies of XIAFLEX for Treatment of Dupuytren's Contracture Presented at American Society for Surgery of the Hand 2013 investment picks
- First patient dosed in Phase 2a randomized, double-blind multiple-dose study - LYNBROOK, N.Y. , Oct.
Sign-up for BioSpecifics Technologies Corp. Announces Initiation of Phase 2a Study of XIAFLEX for Treatment of Cellulite investment picks
2013/11/18
- Results showed comparable improvement in joint contracture and range of motion to single injection in previous studies - - Partner Auxilium expects to submit sBLA - first quarter of 2014 - LYNBROOK, N.Y. , Nov.
Sign-up for BioSpecifics Technologies Corp. Announces Positive Top-line Data from XIAFLEX® MULTICORD Phase IIIb Study investment picks
2014/2/19
LYNBROOK, N.Y. , Feb.
Sign-up for BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences investment picks
2013/12/23
- Did not meet primary endpoint as measured by CT scan but trial demonstrated statistically significant reduction in lipoma surface area in responder analysis as determined by caliper- LYNBROOK, N.Y. , Dec.
Sign-up for BioSpecifics Technologies Corp. Announces Top-line Data from Phase 2 Trial of CCH for Canine Lipoma investment picks
2014/3/6
LYNBROOK, N.Y. , March 6, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results investment picks
LYNBROOK, N.Y. , Aug.
Sign-up for BioSpecifics Technologies Corp. Reports Second Quarter 2013 Financial Results investment picks
LYNBROOK, N.Y. , Nov.
Sign-up for BioSpecifics Technologies Corp. Reports Third Quarter 2013 Financial Results investment picks
2014/4/2
LYNBROOK, N.Y. , April 2, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. to Present at the 13th Annual Needham Healthcare Conference investment picks
LYNBROOK, N.Y. , Sept.
Sign-up for BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference investment picks
2013/9/4
LYNBROOK, N.Y. , Sept.
Sign-up for BioSpecifics Technologies Corp. to Present at the Stifel Nicolaus 2013 Healthcare Conference investment picks
2014/3/10
XIANYANG, China , March 10, 2014 /PRNewsiwre/ -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that it entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain institutional investors for the sale of 1,650,000 shares of common stock in a registered direct offering at the price of $2.49 per share.
Sign-up for Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of Common Stock and Warrants investment picks
2014/2/14
XIANYANG, China , Feb.
Sign-up for Biostar Held Its Strategic Development Seminar; Identified Development Planning for 2014 - 2016 investment picks
2014/3/31
- Annual Revenue Increased to $52.3 Million - Net Income Increased to $809,046, or EPS of $0.06 in FY 2013 XIANYANG, China , March 31, 2014 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the fiscal year ended December 31, 2013 .
Sign-up for Biostar Pharmaceuticals, Inc. Announces Full Year 2013 Financial Results investment picks
2014/1/10
Anticipated Revenue of USD $4 million in 2014 XIANYANG, China , Jan.
Sign-up for Biostar Pharmaceuticals, Inc. Announces Opening of a Sales Office in Gansu Province, PRC investment picks
2013/8/19
XIANYANG, China , Aug.
Sign-up for Biostar Pharmaceuticals, Inc. Announces Second Quarter 2013 Financial Results investment picks
XIANYANG, China , Nov.
Sign-up for Biostar Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: BioShock® Infinite: Burial at Sea – Episode Two Available for Download Starting Today to Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year's USD$21.8 Million Loss from Operations
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity